KRYS
Price
$346.58
Change
+$9.56 (+2.84%)
Updated
Aug 21 closing price
Capitalization
10.26B
78 days until earnings call
Intraday BUY SELL Signals
REPL
Price
$14.77
Change
+$0.72 (+5.12%)
Updated
Aug 21 closing price
Capitalization
1.39B
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KRYS vs REPL

KRYS vs REPL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KRYS vs. REPL commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (KRYS: $346.58 vs. REPL: $14.77)
Brand notoriety: KRYS and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 83% vs. REPL: 55%
Market capitalization -- KRYS: $10.26B vs. REPL: $1.39B
KRYS [@Biotechnology] is valued at $10.26B. REPL’s [@Biotechnology] market capitalization is $1.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 2 FA rating(s) are green whileREPL’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 2 green, 3 red.
  • REPL’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than REPL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 4 TA indicator(s) are bullish while REPL’s TA Score has 6 bullish TA indicator(s).

  • KRYS’s TA Score: 4 bullish, 5 bearish.
  • REPL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, REPL is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а +4.31% price change this week, while REPL (@Biotechnology) price change was -1.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 09, 2026.

REPL is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($10.3B) has a higher market cap than REPL($1.39B). REPL YTD gains are higher at: 51.955 vs. KRYS (40.578). KRYS has higher annual earnings (EBITDA): 185M vs. REPL (-303.89M). KRYS has more cash in the bank: 823M vs. REPL (269M). KRYS has less debt than REPL: KRYS (9.11M) vs REPL (76.3M). KRYS has higher revenues than REPL: KRYS (417M) vs REPL (0).
KRYSREPLKRYS / REPL
Capitalization10.3B1.39B740%
EBITDA185M-303.89M-61%
Gain YTD40.57851.95578%
P/E Ratio43.44N/A-
Revenue417M0-
Total Cash823M269M306%
Total Debt9.11M76.3M12%
FUNDAMENTALS RATINGS
KRYS vs REPL: Fundamental Ratings
KRYS
REPL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
8100
SMR RATING
1..100
4599
PRICE GROWTH RATING
1..100
3834
P/E GROWTH RATING
1..100
16100
SEASONALITY SCORE
1..100
5036

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (55) in the Biotechnology industry is in the same range as KRYS (85) in the Pharmaceuticals Major industry. This means that REPL’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (8) in the Pharmaceuticals Major industry is significantly better than the same rating for REPL (100) in the Biotechnology industry. This means that KRYS’s stock grew significantly faster than REPL’s over the last 12 months.

KRYS's SMR Rating (45) in the Pharmaceuticals Major industry is somewhat better than the same rating for REPL (99) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than REPL’s over the last 12 months.

REPL's Price Growth Rating (34) in the Biotechnology industry is in the same range as KRYS (38) in the Pharmaceuticals Major industry. This means that REPL’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (16) in the Pharmaceuticals Major industry is significantly better than the same rating for REPL (100) in the Biotechnology industry. This means that KRYS’s stock grew significantly faster than REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSREPL
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 19 days ago
80%
Bullish Trend 20 days ago
75%
Declines
ODDS (%)
Bearish Trend 21 days ago
70%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
72%
Bullish Trend 3 days ago
67%
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signal:
Gain/Loss:
REPL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PACB1.350.12
+9.76%
Pacific Biosciences of California
NEO16.980.45
+2.72%
NeoGenomics
EVR291.894.80
+1.67%
Evercore
XLO9.23N/A
N/A
Xilio Therapeutics Inc.
BKHAU12.00N/A
N/A
Black Hawk Acquisition Corp

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+2.84%
VCYT - KRYS
44%
Loosely correlated
+1.24%
AXON - KRYS
43%
Loosely correlated
+2.20%
ACAD - KRYS
43%
Loosely correlated
+1.58%
REPL - KRYS
39%
Loosely correlated
+5.12%
MLTX - KRYS
39%
Loosely correlated
-0.69%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+5.12%
IMNN - REPL
57%
Loosely correlated
+3.80%
SNDX - REPL
49%
Loosely correlated
-0.51%
KYMR - REPL
45%
Loosely correlated
-1.40%
NRIX - REPL
43%
Loosely correlated
-1.22%
ZYME - REPL
42%
Loosely correlated
+7.90%
More